Page 5 - Heart Diseases

No link between heart dysfunction, Covid booster vaccines in India: Experts

New Delhi [India], September 28 (ANI): Clearing the air around the effects of a booster dose of the vaccines, the health experts have said that there is no definite link between heart dysfunction and the precaution doses of the COVID shots.With social media flooded with questions revolving around the effects of booster dose on the human heart, the experts came out in defence of the vaccines.According to Dr Vivek Chaturvedi, Professor & HOD, Cardiology, Amrita Hospital, Faridabad, there have been some instances of heart-related issues in the patients after vaccination, however, there is no conclusive evidence to prove this."This is a very thorny question because we do see heart attacks happening. Not just attacks, sometimes fluid around the heart, sometimes Arrhythmias of the heart after vaccination. But it is very difficult to confirm this because these were happening in the past also," he said.However, Dr Vivek said that COVID can have effects on the heart and the person ...

Heart inflammation risk after Covid-19 booster rare in young men: Study

The risk of developing myocarditis among males ages 16 to 19 years are about one in 15,000 after the third dose of the Pfizer-BioNTech Covid-19 vaccine, however the cases are rare and mild.

Brain stroke, heart-related issues sees uptick after Covid: Experts

Brain stroke, heart-related issues have been on an uptick after the Covid-19 infectios, experts have said

Covid mRNA vaccines safe in patients with heart failure, shows study

Covid mRNA vaccines are associated with a decreased risk of death in patients with heart failure, says a new study

Air pollution linked to deadly heart rhythm disorder, says new study

Exposure to high levels of air pollution is associated with a life-threatening heart condition, according to a study.

Air pollution exposure may lead to heart attack within an hour: Study

Researchers analysed medical data for nearly 1.3 million people treated for heart attacks and unstable angina at 2,239 hospitals in 318 Chinese cities between 2015 and 2020

Alembic gets USFDA nod to market lvabradine used in treating heart failure

Alembic Pharmaceuticals on Wednesday said it has received approval from the US health regulator to market lvabradine tablets, used to treat heart failure, in the American market. The company has received tentative approval from the US Food & Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for lvabradine tablets (5 mg and 7.5 mg), Alembic Pharmaceuticals said in a regulatory filing. The tentatively approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Corlanor Tablets, 5 mg and 7.5 mg, of Amgen Inc. (Amgen). lvabradine Tablets are indicated to reduce the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure. lvabradine Tablets are also indicated for the treatment of stable symptomatic heart failure due to dilated cardiomyopathy (DCM) in pediatric patients aged 6 months and older, who are in sinus rhythm with an elevated heart rate. According to IQVIA, ...

Covid-19 increases risk of heart conditions up to a year later: Study

People who have had COVID-19 are at increased risk of developing cardiovascular complications within the first month to a year after infection, according to a study conducted in the US.

Air pollution linked to heart damage in kidney disease patients: Study

In adults who had chronic kidney disease, air pollution exposure was associated with rising levels of Galectin 3 -- a marker of scarring in the heart

Heart damage plagues Covid-19 survivors a year after infection, study shows

They found non-hospitalised Covid patients had a 39% increased risk of developing heart failure and a 2.2-fold increased risk of a potentially deadly blood clot in the following year

Save yourself a heartache by opting for cardiac cover, say experts

A health insurance plus critical illness combo should suffice for those with a family history of cardiac ailments

New AstraZeneca tie-up to explore vaccine tech for cancer, heart disease

An Imperial College London start-up has tied up with British-Swedish biopharmaceutical major AstraZeneca to explore the therapeutic uses of its vaccine technology

Former VP Pence undergoes surgery to implant pacemaker

Pence, who recently launched a new advocacy group and signed a book deal, had previously been diagnosed with a heart condition.

Ganguly may undergo another angioplasty in 'few days or weeks'

Former India captain Sourav Ganguly will have to undergo another angioplasty in a 'few days or weeks' but for now be discharged from hospital as his condition is 'stable'

Angioplasty on Ganguly's other coronary blockages to be done later

BCCI President Sourav Ganguly is stable and the angioplasty on the two other coronary blockages to be done at an 'immediate later stage'

India Coronavirus Dispatch: Who in the country will be inoculated first?

Lessons from pandemic on tackling air pollution, doctors divided on plasma therapy, and why pet cats are vulnerable to the virus-news relevant to India's fight against Covid-19

Arthritis drug may improve early stages of heart disease, says Study

The study, published in the journal Annals of the Rheumatic Diseases, linked treatment of RA with improvements in vascular stiffness -- an indicator of CVD

Covid-19: Don't ignore exhaustion, chest pain despite no fever, say experts

The suggestion was put forth during a discussion on 'Heart Wellness during Covid-19' hosted by the Associated Chambers of Commerce and Industry (ASSOCHAM) in their Illness to Wellness series on Friday

Combination of hydroxychloroquine, azithromycin increases heart risk: Study

This study, first published on MedRxiv, has already made significant impacts in the healthcare community

Hydroxychloroquine plus azithromycin increases heart risk: Global study

The combination of hydroxychloroquine and azithromycin has been linked to significant cardiovascular risks, including mortality, in the largest safety study ever performed on both HCQ and HCQ+AZM.